Literature DB >> 19477109

Small changes in six-minute walk distance are important in diffuse parenchymal lung disease.

Anne E Holland1, Catherine J Hill, Matthew Conron, Prue Munro, Christine F McDonald.   

Abstract

UNLABELLED: The aim of this study was to determine the minimal important difference for the six-minute walk distance in people with diffuse parenchymal lung disease.
METHODS: Forty-eight subjects (24 idiopathic pulmonary fibrosis) undertook the six-minute walk test before and after an 8-week exercise program. The minimal important difference was calculated using a distribution-based and an anchor-based method. A global rating of change scale was used as the external criterion to judge patients as clinically unchanged or changed.
RESULTS: The mean change in six-minute walk distance in improved subjects was 50.0 m, compared to 4.0 m in unchanged subjects and a reduction of 64.3 m in those classified as worse (p<0.001). The receiver operating characteristic curve indicated a cut-off value for meaningful change of 30.5 m (area under the curve 0.89, 95% confidence interval 0.81-0.98) whilst the standard error of the mean method indicated a value of 33 m. Similar values were obtained when only subjects with idiopathic pulmonary fibrosis were included (29 and 34 m, respectively).
CONCLUSIONS: Small differences in six-minute walk distance, in the range 29-34 m, may be clinically significant for people with diffuse parenchymal lung disease.

Entities:  

Mesh:

Year:  2009        PMID: 19477109     DOI: 10.1016/j.rmed.2009.04.024

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  26 in total

1.  The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.

Authors:  Stephen C Mathai; Milo A Puhan; Diana Lam; Robert A Wise
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  Interstitial lung abnormalities and reduced exercise capacity.

Authors:  Tracy J Doyle; George R Washko; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; Miguel J Divo; Bartolome R Celli; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2012-01-20       Impact factor: 21.405

3.  The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Meilan Han; Rekha Vij; Imre Noth; Eric L Eisenstein; Kevin J Anstrom; Kevin K Brown; Diane Fairclough
Journal:  Respir Med       Date:  2012-07-15       Impact factor: 3.415

4.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake
Journal:  N Engl J Med       Date:  2010-05-18       Impact factor: 91.245

5.  Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease.

Authors:  Randall E Keyser; Joshua G Woolstenhulme; Lisa M K Chin; Steven D Nathan; Nargues A Weir; Gerilynn Connors; Bart Drinkard; James Lamberti; Leighton Chan
Journal:  J Cardiopulm Rehabil Prev       Date:  2015 Jan-Feb       Impact factor: 2.081

6.  Correlation between Six Minute Walk Test and Spirometry in Chronic Pulmonary Disease.

Authors:  Mitali Bharat Agrawal; Nilkanth Tukaram Awad
Journal:  J Clin Diagn Res       Date:  2015-08-01

7.  The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Authors:  Jeffrey J Swigris; Frederick S Wamboldt; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Kevin K Brown
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

8.  Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Diane L Fairclough; Marianne Morrison; Barry Make; Elizabeth Kozora; Kevin K Brown; Frederick S Wamboldt
Journal:  Respir Care       Date:  2011-02-11       Impact factor: 2.258

Review 9.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

Review 10.  Ataluren as an agent for therapeutic nonsense suppression.

Authors:  Stuart W Peltz; Manal Morsy; Ellen M Welch; Allan Jacobson
Journal:  Annu Rev Med       Date:  2012-11-28       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.